← Back to Search

All participants (HIV+ and HIV- drinkers) for HIV/AIDS

N/A
Waitlist Available
Led By Yan Wang, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Study Summary

This study is evaluating whether a wrist-worn alcohol monitor is accurate.

Eligible Conditions
  • HIV/AIDS

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Transdermal Alcohol Concentration (TAC)

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participants (HIV+ and HIV- drinkers)Experimental Treatment3 Interventions
All participants were planned to complete the BACtrack Skyn biosensor in two lab sessions, and wear the Skyn biosensor for two weeks in the field. However, due to COVID, not all participants were able to complete the lab sessions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skyn Monitor Lab Session 2
2019
N/A
~50
Skyn Monitor Lab Session 1
2019
N/A
~50
Skyn Monitor Field Test with EMA App
2019
N/A
~50

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,340 Previous Clinical Trials
715,656 Total Patients Enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
799 Previous Clinical Trials
1,362,462 Total Patients Enrolled
Yan Wang, PhDPrincipal InvestigatorUniversity of Florida
8 Previous Clinical Trials
57,097 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~8 spots leftby Apr 2025